WCY-8-67 (TFA)
WCY-8-67 TFA is an orally active and selective USP5 inhibitor, with an IC50 value of 1.33 μM. WCY-8-67 TFA induces apoptosis and suppresses JAK/STAT3 and PI3K/AKT signaling pathways. WCY-8-67 TFA inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 TFA demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 TFA can be used for the study of acute myeloid leukemia[1].
Product Specifications
UNSPSC
12352005
Target
Akt; Apoptosis; Deubiquitinase; JAK; PI3K; STAT
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Purity
99.40
Smiles
OC(C(F)(F)F)=O.CN(C)CCN(C1=C2C(CN(C3=C4C=CC=CC4=C(F)C=C3)C2)=NC(N5CCNCC5)=N1)C.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
Molecular Formula
C33H36F13N7O8
Molecular Weight
905.66
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (B-K9), CF488A conjugate, 0.1mg/mL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF640R conjugate, 0.1mg/mL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF488A conjugate, 0.1mg/mL
